Uciechowski P, Werfel T, Leo R, Gessner J E, Schubert J, Schmidt R E
Abteilung Immunologie und Transfusionsmedizin, Medizinische Hochschule Hannover, Germany.
Immunobiology. 1992 Jun;185(1):28-40. doi: 10.1016/S0171-2985(11)80315-3.
The Fc gamma RIII receptor (CD16) has been described on natural killer cells and a small subset of T lymphocytes. CD16+bright lymphocytes represent the typical population of peripheral blood CD3- NK cells. In these studies in addition to CD16+bright NK cells Fc gamma RIII expressing cytotoxic T lymphocytes in peripheral blood from one healthy individual are characterized as CD16+dim non-MHC-restricted CTLs either expressing the alpha/beta (80%) or the gamma/delta T cell receptor (20%). Both CD16+ subsets are clearly distinct in their functional capacity performing NK and ADCC activity. Freshly isolated CD16+dim T cells exert higher ADCC, CD16+bright NK cells higher NK activity. They are also differentially activated by interleukin-2 since CD16+bright NK cells reveal a bright expression of the p75 IL-2 receptor beta-chain in contrast to the very low p75 expression on CD16+dim T cells. This activation leads to a gradual increase of ADCC by NK cells. Finally the CD16 expression pattern with low and bright intensity represents a stable phenotype expressed by clones generated from these different subpopulations. On a clonal level CD16+dim non-MHC-restricted T cells can be distinguished from CD16+bright NK cells by their lower capacity in NK killing, but they are equally potent in ADCC. Finally these CD3+CD16+dim clones provide the basis for studies of Fc gamma RIII and TcR interaction.
FcγRIII受体（CD16）已在自然杀伤细胞和一小部分T淋巴细胞上被描述。CD16+高表达淋巴细胞代表外周血CD3-NK细胞的典型群体。在这些研究中，除了CD16+高表达NK细胞外，来自一名健康个体外周血中表达FcγRIII的细胞毒性T淋巴细胞被鉴定为CD16+低表达的非MHC限制性CTL，其中80%表达α/β T细胞受体，20%表达γ/δ T细胞受体。两个CD16+亚群在执行NK和ADCC活性的功能能力上明显不同。新鲜分离的CD16+低表达T细胞具有更高的ADCC活性，CD16+高表达NK细胞具有更高的NK活性。它们也被白细胞介素-2以不同方式激活，因为与CD16+低表达T细胞上极低的p75表达相比，CD16+高表达NK细胞显示出p75白细胞介素-2受体β链的明亮表达。这种激活导致NK细胞的ADCC活性逐渐增加。最后，低强度和高强度的CD16表达模式代表了由这些不同亚群产生的克隆所表达的稳定表型。在克隆水平上，CD16+低表达的非MHC限制性T细胞可以通过其较低的NK杀伤能力与CD16+高表达NK细胞区分开来，但它们在ADCC方面同样有效。最后，这些CD3+CD16+低表达克隆为研究FcγRIII和TcR相互作用提供了基础。
